Status:
COMPLETED
Effects of Ghrelin Administration on Dopamine and Effort
Lead Sponsor:
University Hospital Tuebingen
Collaborating Sponsors:
German Research Foundation
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
20-50 years
Phase:
PHASE1
PHASE2
Brief Summary
Ghrelin is a stomach-derived hormone and the only known circulating peptide that stimulates appetite. Animal studies have conclusively shown that ghrelin increases dopaminergic neurotransmission and, ...
Eligibility Criteria
Inclusion
- Healthy control participants: never fulfilled the criteria of any mood or anxiety disorder (except specific phobia)
- Patients with major depressive disorder: diagnosis according to DSM-5 within 12 months before enrollment and presence of at least mild symptoms at enrollment (BDI II \>= 14)
Exclusion
- lifetime history of a brain injury, schizophrenia, bipolar disorder, and a severe substance use disorder according to DSM-5
- obsessive-compulsive disorder, trauma- and stressor-related disorder, somatic symptom disorder, and eating disorder within a 12-month interval before the test day.
- Neuroimaging Study involving ghrelin infusion: contraindication for PET/MR (e.g., metal implants or prostheses, pregnancy, claustrophobia)
Key Trial Info
Start Date :
February 21 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 6 2024
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT05318924
Start Date
February 21 2022
End Date
August 6 2024
Last Update
December 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Psychiatry & Psychotherapy, University of Tübingen
Tübingen, Baden-Wurttemberg, Germany, 72076